Inovio, AstraZeneca terminate cancer vaccine partnership

MedImmune Ltd., the global biologics research and development arm of AstraZeneca (NYSE: AZN), is terminating a cancer therapy partnership it has with Inovio Pharmaceuticals. The partnership, formed in 2015, gave MedImmune of Gaithersburg, Maryland, exclusive rights to Inovio's experimental DNA-based cancer vaccine, known as INO-3112, for cancers caused by human papillomavirus (HPV) types 16 and 18. MedImmune renamed the new drug candidate as MED10457 after acquirin g its exclusive rights. The…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news